{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:15:40Z","timestamp":1780582540741,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,4,7]],"date-time":"2005-04-07T00:00:00Z","timestamp":1112832000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2005,4,7]],"date-time":"2005-04-07T00:00:00Z","timestamp":1112832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Background<\/jats:title>\n                        <jats:p>The weight-gain caused by many psychotropic drugs is a major cause for poor compliance with such medications and could also increase cardio-vascular morbidity among psychiatric patients. Recent reports have shown that the anticonvulsant topiramate causes weight loss in various patient groups. The drug has also shown effectiveness in open trials as a mood stabilizer in patients with affective disorders, but not in controlled trials in the acute treatment of mania. We used topiramate to treat 12 patients with affective disorders who had a body-mass index &gt;30 kg\/m<jats:sup>2<\/jats:sup>.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>Topiramate was prescribed as part of our routine clinical practice, as an add-on medication, or as a replacement of a mood stabilizer. Patients' weight was recorded in 1 to 2 monthly intervals. Patients were followed up for between 6 and 12 months. The final dose of topiramate varied from 200 to 600 mg\/day.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Topiramate was effective in reducing the weight in 10 out of the 12 patients. At six months the 12 patients had lost a mean of 7.75 kg (SD = 6.9 kg, p &lt; 0.001) and at 12 months 9 patients had lost a mean of 9.61 kg (SD = 6.7 kg, p = 0.003). Three patients stopped the treatment: one due to side effects, one due to possible side effects, and one suffered a manic relapse and showed no sustained weight loss. There were no other clear changes in the course of illness of the patients.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusion<\/jats:title>\n                        <jats:p>The evidence of a strong weight-reducing potential of topiramate is indisputable and clinically significant. Topiramate could be considered in the treatment of bipolar patients who are overweight, or whose concerns about weight gain compromise their compliance with long-term prophylactic medication. So far there is no evidence that topiramate has anti-manic effect and it should not be used as monotherapy.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/1471-244x-5-19","type":"journal-article","created":{"date-parts":[[2005,4,8]],"date-time":"2005-04-08T06:57:49Z","timestamp":1112943469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Add-on topiramate reduces weight in overweight patients with affective disorders: a clinical case series"],"prefix":"10.1186","volume":"5","author":[{"given":"George","family":"Kirov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Tredget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,4,7]]},"reference":[{"issue":"Suppl 8","key":"101_CR1","first-page":"22","volume":"64","author":"LJ Aronne","year":"2003","unstructured":"Aronne LJ, Segal KR: Weight gain in the treatment of mood disorders. J Clin Psychiatry. 2003, 64 (Suppl 8): 22-29.","journal-title":"J Clin Psychiatry"},{"key":"101_CR2","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.4088\/JCP.v64n1205","volume":"64","author":"PE Keck Jr","year":"2003","unstructured":"Keck PE, McElroy SL: Bipolar disorder, obesity and pharmacotherapy-associated weight gain. J Clin Psychiatry. 2003, 64: 1426-1435.","journal-title":"J Clin Psychiatry"},{"key":"101_CR3","doi-asserted-by":"publisher","first-page":"532","DOI":"10.4088\/JCP.v64n0506","volume":"64","author":"CB Nemeroff","year":"2003","unstructured":"Nemeroff CB: Safety of available agents used to treat bipolar disorder: Focus on weight gain. J Clin Psychiatry. 2003, 64: 532-539.","journal-title":"J Clin Psychiatry"},{"key":"101_CR4","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"DB Allison","year":"1999","unstructured":"Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999, 156: 1686-1696.","journal-title":"Am J Psychiatry"},{"key":"101_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1055\/s-2007-979586","volume":"28","author":"T Baptista","year":"1995","unstructured":"Baptista T, Teneud L, Contreras Q, Alastre T, Burguera JL, de Burguera M, de Baptista E, Weiss S, Hernandez L: Lithium and body weight gain. Pharmacopsychiatry. 1995, 28: 35-44.","journal-title":"Pharmacopsychiatry"},{"key":"101_CR6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00003495-199651030-00003","volume":"51","author":"T Silverstone","year":"1996","unstructured":"Silverstone T, Romans S: Long term treatment of bipolar disorder. Drugs. 1996, 51: 367-382.","journal-title":"Drugs"},{"issue":"suppl 11","key":"101_CR7","first-page":"37","volume":"61","author":"M Fava","year":"2000","unstructured":"Fava M: Weight gain and antidepressants. J Clin Psychiatry. 2000, 61 (suppl 11): 37-41.","journal-title":"J Clin Psychiatry"},{"key":"101_CR8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1046\/j.1526-4610.1999.3909633.x","volume":"39","author":"SD Silberstein","year":"1999","unstructured":"Silberstein SD, Collins SD, for the Long-Term Safety of Depakote in Headache Prophylaxis Study Group: Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Headache. 1999, 39: 633-643. 10.1046\/j.1526-4610.1999.3909633.x.","journal-title":"Headache"},{"key":"101_CR9","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2165\/00002018-200124130-00004","volume":"24","author":"P Jallon","year":"2001","unstructured":"Jallon P, Picard F: Body weight gain and anticonvulsants: a comparative review. Drug Safety. 2001, 24: 969-978.","journal-title":"Drug Safety"},{"issue":"Suppl 21","key":"101_CR10","first-page":"16","volume":"60","author":"GS Sachs","year":"1999","unstructured":"Sachs GS, Guille C: Weight gain associated with use of psychotropic medications. J Clin Psychiatry. 1999, 60 (Suppl 21): 16-19.","journal-title":"J Clin Psychiatry"},{"key":"101_CR11","volume-title":"The Genetic Basis of Common Diseases","author":"G Bray","year":"2002","unstructured":"Bray G, Bouchard C, Obesity : The Genetic Basis of Common Diseases. Edited by: King RA, Rotter JI, Motylsky AG. 2002, Oxford University Press, Oxford, 23"},{"key":"101_CR12","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1001\/jama.282.16.1530","volume":"282","author":"DB Allison","year":"1999","unstructured":"Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB: Annual deaths attributable to obesity in the United States. JAMA. 1999, 282: 1530-1538. 10.1001\/jama.282.16.1530.","journal-title":"JAMA"},{"key":"101_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/00004714-200212000-00010","volume":"22","author":"T Suppes","year":"2002","unstructured":"Suppes T: Review of the use of topiramate for treatment of bipolar disorders. J Clin Psychopharmacol. 2002, 22: 599-609. 10.1097\/00004714-200212000-00010.","journal-title":"J Clin Psychopharmacol"},{"key":"101_CR14","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/oby.2003.78","volume":"11","author":"E Ben-Menachem","year":"2003","unstructured":"Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U: Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res. 2003, 11: 556-562.","journal-title":"Obes Res"},{"key":"101_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/oby.2003.102","volume":"11","author":"GA Bray","year":"2003","unstructured":"Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH: A 6-month randomised, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003, 11: 722-733.","journal-title":"Obes Res"},{"key":"101_CR16","doi-asserted-by":"publisher","first-page":"368","DOI":"10.4088\/JCP.v61n0508","volume":"61","author":"NA Shapira","year":"2000","unstructured":"Shapira NA, Goldsmith TD, MsElroy SL: Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry. 2000, 61: 368-372.","journal-title":"J Clin Psychiatry"},{"key":"101_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1176\/appi.ajp.160.2.255","volume":"160","author":"SL McElroy","year":"2003","unstructured":"McElroy SL, Arnold LM, Shapira NA, Keck PE, Rosenthal NR, Karim MR, Kamin M, Hudson JI: Topiramate in the treatment of binge eating disorder associated with obesity: a randomsied, placebo-controlled trial. Am J Psychiatry. 2003, 160: 255-261. 10.1176\/appi.ajp.160.2.255.","journal-title":"Am J Psychiatry"},{"key":"101_CR18","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.4088\/JCP.v65n1104","volume":"65","author":"SL McElroy","year":"2004","unstructured":"McElroy SL, Shapira NA, Arnold LM, Keck PE, Rosenthal NR, Wu SC, Capece JA, Fazzio L, Hudson JI: Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry. 2004, 65: 1463-9.","journal-title":"J Clin Psychiatry"},{"key":"101_CR19","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.4088\/JCP.v64n1208","volume":"64","author":"DW Hedges","year":"2003","unstructured":"Hedges DW, Reimherr FW, Hoopes SP, Rosenthal NR, Kamin M, Karim R, Capece JA: Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry. 2003, 64: 1449-1454.","journal-title":"J Clin Psychiatry"},{"key":"101_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0165-0327(98)00110-4","volume":"50","author":"D Marcotte","year":"1998","unstructured":"Marcotte D: Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord. 1998, 50: 245-251. 10.1016\/S0165-0327(98)00110-4.","journal-title":"J Affect Disord"},{"key":"101_CR21","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0006-3223(99)00316-9","volume":"47","author":"SL McElroy","year":"2000","unstructured":"McElroy SL, Suppes T, Keck PE, Frye MA, Denicoff KD, Altshuler LL, Brown ES, Nolen WA, Kupka RW, Rochussen J, Leverich GS, Post RM: Open-lable adjunctive topiramtae in the treatment of bipolar disorders. Biol Psychiatry. 2000, 47: 1025-1033. 10.1016\/S0006-3223(99)00316-9.","journal-title":"Biol Psychiatry"},{"key":"101_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4088\/PCC.v02n0304","volume":"2","author":"S Gupta","year":"2000","unstructured":"Gupta S, Masand PS, Frank BL, Lockwood KL, Keller PL: Topiramate in Bipolar and Schizoaffective Disorders: Weight Loss and Efficacy. Prim Care Companion J Clin Psychiatry. 2000, 2: 96-100.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"101_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/00004714-200208000-00017","volume":"22","author":"E Vieta","year":"2002","unstructured":"Vieta E, Torrent C, Garcia-Ribas G, Gilabert A, Garcia-Pares G, Rodriguez A, Cadevall J, Garcia-Castrillon J, Lusilla P, Arrufat F: Use of topiramate in treatment-resistant bipolar spectrum disorders. J Clin Psychopharmacol. 2002, 22: 431-435. 10.1097\/00004714-200208000-00017.","journal-title":"J Clin Psychopharmacol"},{"key":"101_CR24","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S0278-5846(01)00278-0","volume":"26","author":"C Guille","year":"2002","unstructured":"Guille C, Sachs G: Clinical outcome of adjunctive topiramate treatment in a sample of refractory bipolar patinets with comorbid conditions. Prog Neuropsychopharmacol Biol Psychiatry. 2002, 26: 1035-1039. 10.1016\/S0278-5846(01)00278-0.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"101_CR25","doi-asserted-by":"publisher","first-page":"834","DOI":"10.4088\/JCP.v64n0715","volume":"64","author":"E Vieta","year":"2003","unstructured":"Vieta E, Goikolea JM, Olivares JM, Gonzalez-Pinto A, Rodriguez A, Colom F, Comes M, Torrent C, Sanchez-Moreno J: 1-year follow-up of patients treated with risperidone and topiramate for a manic episode. J Clin Psychiatry. 2003, 64: 834-839.","journal-title":"J Clin Psychiatry"},{"key":"101_CR26","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/01.jcp.0000130556.01373.45","volume":"24","author":"E Vieta","year":"2004","unstructured":"Vieta E, Sanchez-Moreno J, Goikolea JM, Colom F, Martinez-Aran A, Benabarre A, Corbella B, Torrent C, Comes M, Reinares M, Brugue E: Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psychopharmacol. 2004, 24: 374-8. 10.1097\/01.jcp.0000130556.01373.45.","journal-title":"J Clin Psychopharmacol"},{"key":"101_CR27","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/S0149-2918(02)80061-3","volume":"24","author":"KN Chengappa","year":"2002","unstructured":"Chengappa KN, Chalasani L, Braar JS, Parepally H, Houck P, Levine J: Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label nonrandomised chart review. Clin Ther. 2002, 24: 1576-1584. 10.1016\/S0149-2918(02)80061-3.","journal-title":"Clin Ther"},{"key":"101_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1034\/j.1399-5618.1999.10111.x","volume":"1","author":"KN Chengappa","year":"1999","unstructured":"Chengappa KN, Rathore D, Levine J, Atzert R, Solai L, Parepally H, Levin H, Moffa N, Delaney J, Brar JS: Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord. 1999, 1: 42-53. 10.1034\/j.1399-5618.1999.10111.x.","journal-title":"Bipolar Disord"},{"key":"101_CR29","doi-asserted-by":"publisher","first-page":"464","DOI":"10.4088\/JCP.v62n0610","volume":"62","author":"HC Grunze","year":"2001","unstructured":"Grunze HC, Normann C, Langosch J, Schaefer M, Amann B, Sterr A, Schloesser S, Kleindiest N, Walden J: Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. J Clin Psychiatry. 2001, 62: 464-468.","journal-title":"J Clin Psychiatry"},{"key":"101_CR30","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0278-5846(01)00323-2","volume":"26","author":"VP Bozikas","year":"2002","unstructured":"Bozikas VP, Petrikis P, Kourtis A, Youlis P, Karavatos A: Treatment of acute mania with topiramate in hospitalised patients. Prog Neuropsychopharmacol Biol Psychaitry. 2002, 26: 1203-1206. 10.1016\/S0278-5846(01)00323-2.","journal-title":"Prog Neuropsychopharmacol Biol Psychaitry"},{"key":"101_CR31","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/00004714-200106000-00015","volume":"21","author":"JR Calabrese","year":"2001","unstructured":"Calabrese JR, Keck PE, McElroy SL, Shelton MD: A pilot study of topiramate in the treatment of acute mania. J Clin Psychopharmacol. 2001, 21: 340-342. 10.1097\/00004714-200106000-00015.","journal-title":"J Clin Psychopharmacol"},{"key":"101_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1023\/A:1014627001201","volume":"13","author":"SN Ghaemi","year":"2001","unstructured":"Ghaemi SN, Manwani SG, Katzow JJ, Ko JY, Goodwin FK: Topiramate treatment of bipolar disorders: a retrospective chart review. Ann ClinPsychiatry. 2001, 13: 185-189. 10.1023\/A:1014627001201.","journal-title":"Ann ClinPsychiatry"},{"key":"101_CR33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1034\/j.1399-5618.2002.01189.x","volume":"4","author":"RS McIntyre","year":"2002","unstructured":"McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH: Topiramate versus bupropion SR when added to mood stabiliser therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord. 2002, 4: 207-213. 10.1034\/j.1399-5618.2002.01189.x.","journal-title":"Bipolar Disord"},{"key":"101_CR34","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1185\/030079904125003665","volume":"20","author":"L Lykouras","year":"2004","unstructured":"Lykouras L, Hatzimanolis J: Adjunctive topiramate in the maintenance treatment of bipolar disorders: an open-label study. Curr Med Res Opin. 2004, 20: 843-7.","journal-title":"Curr Med Res Opin"},{"issue":"suppl 10","key":"101_CR35","first-page":"28","volume":"65","author":"LN Yatham","year":"2004","unstructured":"Yatham LN: Newer Anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry. 2004, 65 (suppl 10): 28-35.","journal-title":"J Clin Psychiatry"},{"issue":"suppl 2","key":"101_CR36","first-page":"51","volume":"6","author":"National Heart Lung and Blood Institute (NHLBI) Obesity Task Force","year":"1998","unstructured":"National Heart Lung and Blood Institute (NHLBI) Obesity Task Force: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res. 1998, 6 (suppl 2): 51-209.","journal-title":"Obes Res"},{"key":"101_CR37","volume-title":"BMA & RPSGB, London","author":"British Medical Association & Royal Pharmaceutical Society of Great Britain","year":"2004","unstructured":"British Medical Association & Royal Pharmaceutical Society of Great Britain: British National Formulary (BNF 48). BMA & RPSGB, London. 2004, [http:\/\/www.bnf.org]"},{"key":"101_CR38","unstructured":"National Center for Health statistics: National Health Interview Survey (NHIS). [http:\/\/www.cdc.gov\/nchs\/about\/major\/nhis\/released200202\/figure06_2.htm]"},{"key":"101_CR39","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0165-0327(90)90077-L","volume":"18","author":"J Aagaard","year":"1990","unstructured":"Aagaard J, Vestergaard P: Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study. J Affect Disorders. 1990, 18: 259-266. 10.1016\/0165-0327(90)90077-L.","journal-title":"J Affect Disorders"},{"key":"101_CR40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0165-0327(01)00377-9","volume":"68","author":"F Angst","year":"2002","unstructured":"Angst F, Stassen HH, Clayton PJ, Angst J: Mortality of patients with mood disorders: follow-up over 34\u201338 years. J Affect Disord. 2002, 68: 167-181. 10.1016\/S0165-0327(01)00377-9.","journal-title":"J Affect Disord"},{"key":"101_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/00131746-200101000-00005","volume":"7","author":"PL Weiden","year":"2001","unstructured":"Weiden PL, Miller AL: Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. J Psychiatr Pract. 2001, 7: 41-47. 10.1097\/00131746-200101000-00005.","journal-title":"J Psychiatr Pract"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-5-19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/1471-244X-5-19\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-5-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-5-19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T12:53:05Z","timestamp":1728305585000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-5-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,7]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2005,12]]}},"alternative-id":["101"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-5-19","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,7]]},"assertion":[{"value":"30 November 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"19"}}